title: Combination therapy with transfer factor and high dose stronger neo-minophagen C in chronic hepatitis B in children (HBe Ag positive).
abstract: This study mainly describes the efficacy of the combination therapy with Transfer Factor (TF) and high dose Stronger Neo-Minophagen C (SNMC) for HBV carrier children with HBe Ag positive chronic hepatitis. There were 12 patients, 10 males and 2 females aged from 7 months to 14 years 8 months. Liver biopsy was done in 11 patients, and the histopathological findings of the liver were chronic active hepatitis (8 cases) and chronic inactive hepatitis (3 cases). In 6 of 8 patients, HBe-Ag became negative (75%) within 18 weeks (mean 8 weeks) after the initiation of the combination therapy with TF and SNMC (HBe-seronegative), and 4 of these 8 patients (50%) became anti-HBe positive within 29 weeks (mean 15 weeks) (HBe-seroconversion). These results suggest that combination therapy with TF and high dose SNMC may be beneficial in the treatment of chronic hepatitis B in children.
authors.affiliation: Department of Pediatrics, Wakayama Medical College, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sumiyama
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: E
authors.initials: E
authors.lastname: Miyashiro
authors.forename: M
authors.initials: M
authors.lastname: Koike
mesh_terms: D000293:Adolescent; D000998:Antiviral Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003545:Cysteine / Q000008:administration & dosage*; D004338:Drug Combinations; D005260:Female; D005998:Glycine / Q000008:administration & dosage*; D006034:Glycyrrhetinic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D019695:Glycyrrhizic Acid; D006509:Hepatitis B / Q000276:immunology / Q000628:therapy*; D006513:Hepatitis B e Antigens / Q000032:analysis; D006521:Hepatitis, Chronic / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D009828:Oleanolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012996:Solutions; D013997:Time Factors; D014165:Transfer Factor / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D004338:Drug Combinations; D006513:Hepatitis B e Antigens; D012996:Solutions; D014165:Transfer Factor; D019695:Glycyrrhizic Acid; D009828:Oleanolic Acid; C009781:neominophagen C; D003545:Cysteine; D006034:Glycyrrhetinic Acid; D005998:Glycine